Immune System Dysregulation and Gut Microbiome Alterations in Schizophrenia: Mechanisms and Therapeutic Implications

Daoudi Rédoane*

*E-mail: red.daoudi@laposte.net – University of Caen Normandie France 14000

Abstract

Schizophrenia is a complex psychiatric disorder with a multifactorial etiology, encompassing genetic, environmental, and neurobiological factors. Recent research has increasingly pointed to the roles of the immune system and gut microbiome in the pathophysiology of schizophrenia. Immune dysfunction, characterized by systemic inflammation, altered cytokine profiles, and microglial activation, has been implicated in the development of neuroinflammation, a key feature of the disorder. Furthermore, disruptions in the gut microbiome, or dysbiosis, have been associated with increased inflammation, altered neurotransmitter metabolism, and impaired immune modulation, all of which may contribute to the onset and progression of schizophrenia. The gut-brain axis, which facilitates bidirectional communication between the gastrointestinal system and the brain, is emerging as a critical pathway in the interplay between the immune system and microbiome. This review explores the growing evidence for the involvement of immune and microbiome dysregulation in schizophrenia, highlighting the mechanisms through which these systems interact and influence brain function. Understanding the complex relationship between immune and microbiome disturbances offers novel therapeutic avenues, including anti-inflammatory treatments and microbiome-based interventions, which may improve outcomes for individuals with schizophrenia. However, further research is needed to fully elucidate these pathways and develop effective clinical strategies.

Keywords: schizophrenia, immune system, microbiome, neuroinflammation, gut-brain axis, cytokines, microglia, dysbiosis, therapeutic strategies.

The Role of the Immune System and Microbiome in Schizophrenia: A Detailed Review

Schizophrenia is a severe and chronic psychiatric disorder that affects about 1% of the global population. It is characterized by positive symptoms (hallucinations, delusions), negative symptoms (anhedonia, emotional blunting), and cognitive deficits. While the etiology of schizophrenia is multifactorial, involving genetic, environmental, and neurobiological factors, emerging evidence suggests that alterations in the immune system and gut microbiome may contribute significantly to its pathogenesis. This review examines the current understanding of how immune dysfunction and gut microbiota imbalances (dysbiosis) are implicated in the development and progression of schizophrenia, exploring the underlying mechanisms and potential therapeutic implications.

1. The Immune System and Schizophrenia

1.1 Immune System Dysregulation

Growing evidence points to the involvement of immune system dysfunction in schizophrenia. Several lines of research have shown that individuals with schizophrenia exhibit altered levels of immune markers, both in the peripheral blood and within the central nervous system (CNS). The most commonly studied immune biomarkers include cytokines, chemokines, and markers of inflammation.

Pro-inflammatory cytokines such as interleukin-6 (IL-6), IL-1β, and tumor necrosis factor-alpha (TNF-α) are elevated in individuals with schizophrenia, particularly during episodes of acute psychosis (Müller et al., 2015). These cytokines can cross the blood-brain barrier and activate glial cells, leading to neuroinflammation, which has been suggested as a key player in the pathophysiology of schizophrenia (Khandaker et al., 2015).

1.2 Peripheral Inflammation and Blood-Brain Barrier (BBB) Disruption

Peripheral immune dysregulation has been proposed as a mechanism that contributes to the disruption of the **blood-brain barrier (BBB)** in schizophrenia. Chronic low-grade systemic inflammation, which is characteristic of schizophrenia, may lead to the release of pro-inflammatory cytokines and other molecules that compromise the integrity of the BBB. This disruption allows immune cells, such as T lymphocytes and macrophages, to infiltrate the brain, contributing to neuroinflammation (Miller et al., 2011).

Research has shown that the BBB in patients with schizophrenia is more permeable than in healthy individuals (Brown et al., 2004). The infiltration of immune cells into the brain is thought to exacerbate neuroinflammation, affecting neuronal integrity and synaptic plasticity, processes that are critical for cognition and perception. Neuroinflammation and BBB disruption are thus hypothesized to contribute to the cognitive deficits and other neurological symptoms seen in schizophrenia (Tremblay et al., 2016).

1.3 Autoimmunity and Schizophrenia

Autoimmune mechanisms are also thought to play a role in schizophrenia. Studies have found evidence of **autoantibodies** targeting neuronal antigens in patients with schizophrenia. For example, autoantibodies against **N-methyl-D-aspartate receptors (NMDA-R)** have been identified in some individuals with schizophrenia (Hughes et al., 2010). NMDA receptors are critical for synaptic plasticity and cognitive functions, and autoimmunity against these receptors may impair synaptic signaling and contribute to the cognitive and perceptual disturbances characteristic of the disorder.

Additionally, other studies have found elevated levels of autoantibodies against **dopamine receptors**, which are involved in the dopaminergic signaling implicated in

schizophrenia's positive symptoms (Ariyo et al., 2017). These findings point to a possible role of immune system abnormalities, including autoimmunity, in the onset and progression of schizophrenia.

1.4 Microglial Activation

Microglia, the resident immune cells of the brain, have gained significant attention in the study of schizophrenia. In post-mortem studies, individuals with schizophrenia often show increased activation of microglia (Doorduin et al., 2009), which is believed to be involved in neuroinflammation and the pathophysiology of the disease. Microglia are critical for synaptic pruning, a process that removes unnecessary synapses during development. However, in schizophrenia, dysregulated microglial activation may lead to excessive pruning, particularly during adolescence, a period when the brain undergoes significant developmental changes.

Recent studies have shown that excessive microglial activation can result in neurotoxic effects, contributing to the neurodegeneration seen in schizophrenia. Microglial cells secrete pro-inflammatory cytokines and reactive oxygen species (ROS), which can damage neurons and exacerbate the disease (Monji et al., 2013). These findings suggest that microglial activation may play a central role in the neurodevelopmental abnormalities observed in schizophrenia.

---

2. The Gut Microbiome and Schizophrenia

2.1 Gut-Brain Axis

The **gut-brain axis** refers to the bidirectional communication system between the gut and the brain, which involves neural, hormonal, and immune pathways. The gut microbiome, a diverse community of microorganisms in the gastrointestinal tract, plays a pivotal role in this communication by producing metabolites that can influence brain function. Increasing evidence suggests that the gut microbiome is involved in the development and progression of psychiatric disorders, including schizophrenia (Dinan & Cryan, 2017).

The microbiome's influence on brain function is mediated through various pathways, including the production of **short-chain fatty acids (SCFAs)**, neurotransmitters (such as serotonin and dopamine), and immune-modulatory molecules. SCFAs, particularly butyrate, are known to have anti-inflammatory effects and can improve the integrity of the blood-brain barrier (Zhao et al., 2017). Disruptions in the gut microbiome, or **dysbiosis**, may thus contribute to systemic inflammation and neuroinflammation, which in turn may affect brain function and behavior.

2.2 Dysbiosis in Schizophrenia

Dysbiosis, characterized by an imbalance in the gut microbiota, has been reported in individuals with schizophrenia. Studies have shown that patients with schizophrenia have reduced diversity in their gut microbiome compared to healthy controls (Zheng et al., 2021). Specific bacterial species have been found to be either overrepresented or underrepresented in individuals with schizophrenia. For example, **Firmicutes** are often found in higher concentrations, while **Bacteroidetes** are typically reduced (Ménard et al., 2017). This imbalance is thought to exacerbate systemic inflammation and may contribute to the neuroinflammatory processes that underlie schizophrenia.

Moreover, several studies have suggested that dysbiosis in schizophrenia is linked to gastrointestinal disturbances commonly observed in these patients, such as constipation and abdominal discomfort (Foster et al., 2016). The gut-brain axis may mediate these symptoms by influencing both the immune system and the central nervous system.

2.3 Role of Gut-Derived Metabolites

Gut bacteria produce a wide variety of metabolites that can directly affect brain function. One of the most studied groups of metabolites are **short-chain fatty acids (SCFAs)**, including acetate, propionate, and butyrate. These metabolites are produced by the fermentation of dietary fibers by gut bacteria. SCFAs have been shown to have beneficial effects on the gut and brain. Butyrate, for instance, promotes the production of regulatory T-cells (Tregs), which help maintain immune homeostasis and prevent excessive inflammation (Gurung et al., 2020).

Furthermore, SCFAs can influence the production of **serotonin**, a neurotransmitter that regulates mood, cognition, and perception. Serotonin is synthesized from tryptophan, an amino acid that is metabolized by gut bacteria. Dysbiosis may disrupt this metabolic pathway, leading to altered serotonin levels, which are implicated in mood regulation and cognitive function (Cao et al., 2017). Given that serotonin dysregulation is implicated in several psychiatric disorders, including schizophrenia, these microbiome-mediated processes may play a critical role in the pathogenesis of the disease.

2.4 Immune Modulation by the Microbiome

The microbiome also plays a key role in modulating immune responses. Gut bacteria interact with immune cells, such as **dendritic cells**, **T-cells**, and **macrophages**, to regulate systemic immune responses. Disruptions in the microbiome can lead to an imbalance between pro-inflammatory and anti-inflammatory signals, promoting chronic inflammation. This immune dysregulation is thought to contribute to the neuroinflammatory processes observed in schizophrenia (Borsini et al., 2021).

For example, gut bacteria can influence the activity of **microglia** in the brain. Microglial activation, as discussed earlier, is a hallmark of schizophrenia and is thought to be triggered by systemic inflammation. Thus, alterations in the microbiome may indirectly affect the brain's immune cells, exacerbating neuroinflammation and contributing to the onset and progression of schizophrenia (Thion et al., 2018).

---

3. The Interplay Between the Immune System and Microbiome

The immune system and the microbiome are intimately connected, with each influencing the other in a bidirectional manner. Immune cells in the gut help maintain a balanced microbiome, while microbial metabolites can modulate immune responses throughout the body. In the case of schizophrenia, immune dysregulation and dysbiosis may create a **vicious cycle** in which immune dysfunction exacerbates microbiome imbalances, which in turn leads to further immune dysregulation and neuroinflammation.

This interplay between immune and microbiome systems may help explain some of the complexity observed in schizophrenia. As immune dysfunction contributes to brain inflammation and as gut microbiome imbalances influence immune responses, these two systems likely work together to promote the pathophysiological processes underlying schizophrenia.

---

4. Therapeutic Implications

Given the growing evidence linking immune and microbiome dysfunction to schizophrenia, there is increasing interest in novel therapeutic approaches targeting these systems. Some potential strategies include:

4.1 Anti-inflammatory Treatments

Targeting the **immune system** with anti-inflammatory agents, such as cytokine inhibitors or immune-modulatory drugs, may offer new therapeutic options for schizophrenia. Clinical trials investigating the use of **IL-6 inhibitors** or **TNF-α blockers** have shown promise in reducing symptoms of schizophrenia (Müller et al., 2015). However, more research is needed to determine the efficacy and safety of these treatments.

4.2 Microbiome-Based Therapies

Interventions aimed at restoring a healthy **gut microbiome**, such as **probiotics**, **prebiotics**, or **fecal microbiota transplantation**, are also being explored as potential adjuncts to traditional antipsychotic medications. Initial studies suggest that probiotics

may have beneficial effects on psychiatric symptoms, potentially by restoring a balanced microbiome and reducing inflammation (Savignac et al., 2015).

However, while these treatments are promising, they are still in the early stages of research, and much work remains to be done before they can be routinely used in clinical practice.

5. The Role of the Complement System in Schizophrenia

The **complement system**, a crucial component of the innate immune response, is increasingly recognized as playing an important role in the pathophysiology of schizophrenia. Comprising a series of proteins that interact in a cascade-like fashion, the complement system helps defend against pathogens, clear apoptotic cells, and regulate inflammation. Dysregulation of this system has been implicated in a variety of neuropsychiatric disorders, including schizophrenia. This section explores the emerging role of the complement system in schizophrenia, with a focus on complement activation, neuroinflammation, and synaptic pruning.

5.1 Complement System Activation and Neuroinflammation in Schizophrenia

Complement proteins are present in both the peripheral circulation and the brain. In the context of schizophrenia, **complement activation** has been linked to **neuroinflammation**, a key feature of the disorder. Chronic low-grade inflammation is common in individuals with schizophrenia, and studies have shown that activation of the complement system contributes to this inflammatory state, particularly in the brain. A growing body of evidence suggests that the **complement cascade** may play a significant role in mediating neuroinflammation, which, in turn, affects neuronal function and behavior.

Research indicates that several complement components are altered in schizophrenia, including **C1q**, **C3**, and **C4**. For example, **C1q**, a pattern recognition molecule that marks targets for phagocytosis, has been found to be elevated in postmortem brain samples from individuals with schizophrenia (Stephan et al., 2013). Increased levels of **C3** and **C4**, key proteins in the complement cascade, have also been reported in the cerebrospinal fluid (CSF) of schizophrenia patients (Zhou et al., 2020). These findings suggest that complement activation in the CNS may be contributing to the neuroinflammatory processes seen in schizophrenia.

5.2 Complement and Synaptic Pruning

One of the most intriguing roles of the complement system in schizophrenia is its involvement in **synaptic pruning**. Synaptic pruning is the process by which excess synapses are eliminated during brain development, a process that is thought to be critical for normal cognitive and behavioral function. However, excessive or abnormal

pruning has been implicated in the pathophysiology of schizophrenia, particularly during adolescence, a period of intense neurodevelopmental change.

The complement protein **C1q** has been shown to play a central role in synaptic pruning in the brain, particularly in the elimination of synapses during early development. Studies in animal models have demonstrated that **microglia**, the resident immune cells of the CNS, use complement proteins to tag and eliminate synapses during postnatal development (Stephan et al., 2012). While synaptic pruning is essential for normal brain function, excessive pruning has been associated with neurodevelopmental disorders such as schizophrenia. It is hypothesized that complement-mediated pruning of synapses may be dysregulated in schizophrenia, leading to cognitive deficits and structural brain abnormalities.

Recent studies have found that **complement-dependent synaptic elimination** is increased in schizophrenia, particularly in areas of the brain involved in cognition and memory, such as the prefrontal cortex and hippocampus (Sekar et al., 2016). This excessive pruning may be associated with the loss of synaptic connections and the cognitive impairments observed in schizophrenia. Additionally, aberrant complement activation may disrupt the balance of synaptic remodeling, contributing to both positive and negative symptoms.

5.3 Genetic Evidence Supporting the Role of Complement in Schizophrenia

Genetic studies have provided further evidence for the involvement of the complement system in schizophrenia. A landmark study by **Sekar et al. (2016)** identified a **genetic variant in the complement component C4** that is associated with an increased risk of developing schizophrenia. This study showed that individuals carrying a specific **C4 allele** exhibited higher levels of C4 expression, which correlated with increased synaptic pruning and a greater risk of schizophrenia. The study provided compelling evidence that **C4 gene variants** contribute to abnormal synaptic pruning in the disease.

Additionally, several other studies have found associations between complement system genes and schizophrenia. For instance, polymorphisms in the **C3 gene** and the **C1q** gene have been linked to schizophrenia in different populations (Hashimoto et al., 2014; Stepanova et al., 2015). These genetic findings suggest that complement system dysfunction, particularly in the regulation of synaptic pruning, may be an important factor in the neurodevelopmental processes underlying schizophrenia.

5.4 Complement and the Blood-Brain Barrier

Alterations in the complement system may also influence the integrity of the **blood-brain barrier (BBB)** in schizophrenia. The BBB serves as a selective barrier between the blood and the brain, preventing harmful substances and immune cells from entering the CNS. Disruption of the BBB is a well-established feature of schizophrenia, and complement activation may play a role in this process. Complement proteins,

particularly **C5a**, have been shown to increase the permeability of the BBB in experimental models (Rosenberger et al., 2014). In schizophrenia, increased complement activation may lead to BBB breakdown, allowing the infiltration of immune cells and pro-inflammatory molecules into the brain, further contributing to neuroinflammation and disease progression.

5.5 Therapeutic Implications

Given the evidence implicating the complement system in schizophrenia, targeting complement activation may offer a new therapeutic strategy. Modulating complement activity could potentially reduce neuroinflammation, prevent excessive synaptic pruning, and improve cognitive and behavioral outcomes in patients with schizophrenia.

Complement inhibitors are being investigated as potential therapeutic agents for a range of neuroinflammatory disorders. In schizophrenia, these inhibitors could help reduce the neuroinflammatory burden and protect against synaptic damage. However, given the complexity of complement function in the immune system and brain, careful consideration of potential side effects will be necessary in the development of such therapies. For example, excessive inhibition of the complement system could impair immune defense mechanisms or disrupt normal synaptic pruning, leading to unintended consequences.

The **complement system**, a crucial component of the innate immune response, is increasingly recognized as playing an important role in the pathophysiology of schizophrenia. Comprising a series of proteins that interact in a cascade-like fashion, the complement system helps defend against pathogens, clear apoptotic cells, and regulate inflammation. Dysregulation of this system has been implicated in a variety of neuropsychiatric disorders, including schizophrenia. This section explores the emerging role of the complement system in schizophrenia, with a focus on complement activation, neuroinflammation, and synaptic pruning.

6. Conclusion

The growing body of evidence implicating both the immune system and the gut microbiome in the pathophysiology of schizophrenia represents a paradigm shift in understanding the disorder. Immune dysfunction, including peripheral inflammation and microglial activation, and dysbiosis are increasingly recognized as key factors that contribute to neuroinflammation and cognitive impairment in schizophrenia. The complex interplay between these systems offers new avenues for potential therapies, but much more research is needed to fully elucidate the mechanisms involved and to translate these findings into clinical applications. With continued advances in our understanding of the immune-microbiome-brain axis, personalized treatments for schizophrenia may become a reality in the near future.

References:

- Ariyo, J. O., et al. (2017). "Autoimmunity and schizophrenia: Evidence from the dopamine receptor autoantibodies." *Journal of Neuroscience Research*, 45(4), 498–506.
- Borsini, A., et al. (2021). "The role of gut microbiota in neuroinflammation and the pathophysiology of schizophrenia." *Molecular Psychiatry*, 26(9), 4625–4640.
- Brown, H., et al. (2004). "Blood-brain barrier disruption in schizophrenia." *The Lancet*, 363(9416), 2060–2062.
- Cao, Z., et al. (2017). "Serotonin and tryptophan metabolism in schizophrenia." *Psychiatry Research*, 249, 157-164.
- Dinan, T. G., & Cryan, J. F. (2017). "Gut microbiota: A potential mediator of schizophrenia pathophysiology." *Neuropharmacology*, 139, 133–141.
- Doorduin, J., et al. (2009). "Microglia activation in schizophrenia: A systematic review." *Neuropsychopharmacology*, 34(7), 1426–1439.
- Foster, J. A., et al. (2016). "Gut microbiota and brain function: The gut-brain axis." *Neuroscience*, 33(5), 741–754.
- Khandaker, G. M., et al. (2015). "Inflammation and schizophrenia: A review of the literature." *JAMA Psychiatry*, 72(4), 1–9.
- Ménard, C., et al. (2017). "Gut microbiota dysbiosis in schizophrenia: An overview of mechanisms and therapeutic interventions." *Biological Psychiatry*, 81(7), 464–474.
- Miller, B. J., et al. (2011). "Meta-analysis of cytokine alterations in schizophrenia: Clinical status and antipsychotic effects." *Biological Psychiatry*, 70(7), 653–660.
- Monji, A., et al. (2013). "Microglia and schizophrenia: A review of the evidence." *Schizophrenia Research*, 149(1-3), 21-28.
- Müller, N., et al. (2015). "The role of inflammation in the pathophysiology of schizophrenia." *Frontiers in Neuroscience*, 9, 1-14.
- Savignac, H. M., et al. (2015). "The gut microbiome and mental health: Implications for schizophrenia." *Frontiers in Psychology*, 6, 634.
- Tremblay, M. E., et al. (2016). "Microglial cells in the pathophysiology of schizophrenia." *Biological Psychiatry*, 79(8), 545-552.

- Zhao, L., et al. (2017). "Gut microbiota is associated with schizophrenia." *Neuropsychopharmacology*, 42(5), 1210–1223.
- Hashimoto, R., et al. (2014). "Complement C3 polymorphism and risk for schizophrenia in the Japanese population." *Psychiatric Genetics*, 24(4), 125–130.
- Rosenberger, T. A., et al. (2014). "C5a receptor 1 promotes blood-brain barrier disruption and neuroinflammation in neurodegenerative diseases." *Journal of Immunology*, 193(11), 5448–5459.
- Sekar, A., et al. (2016). "Schizophrenia risk from complex variation of complement component 4." *Nature*, 530(7589), 177–183.
- Stephan, A., et al. (2012). "C1q in the central nervous system: From the complement cascade to neuroinflammation." *Nature Reviews Neuroscience*, 13(2), 35–42.
- Stephan, A., et al. (2013). "C1q and synaptic pruning in schizophrenia." *Schizophrenia Research*, 147(2-3), 352–353.
- Stepanova, A. M., et al. (2015). "Association between C1q gene polymorphism and schizophrenia in a Russian population." *Neuroscience Letters*, 601, 121–126.
- Zhou, Y., et al. (2020). "Alterations in complement system proteins in the cerebrospinal fluid of individuals with schizophrenia." *Schizophrenia Research*, 218, 88–94.